Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused ...

Merck Animal Health plans a $985 million expansion of its manufacturing facility in De Soto. Merck Animal Health's expansion ...

A Manhattan federal jury found Merck & Co. discriminated against a director of compliance and risk management by terminating ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its ...

De Soto planners have delayed approval of Merck Animal Health's site plan to review fire lane and traffic flow details for the animal vaccine maker's expansion.

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Merck MRK continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the ...

Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the ...

Shares of Merck and UnitedHealth are seeing strong returns Tuesday morning, sending the Dow Jones Industrial Average into positive territory.

Kelun Biotech's sac-TMT plus Merck's Keytruda shows significant progress in late-stage lung cancer trial. Read more here.